drugset

drugset / Trial / NCT05924620

Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism

NCT05924620 ↗

Phase 4 Completed 60 enrolled Chongqing Medical University

RandomizedParallel-groupOpen-labelTreatment

Summary

To study the efficacy and safety of finerenone in patients with primary aldosteronism

Timeline

Start: 2023-06-21
Primary completion: 2024-03-12
Completion: 2024-03-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Finerenone	Small molecule	20 mg	—

Indications